search icon
      blog search icon

      ADMA Biologics, Inc. (ADMA) Stock Declining in Aftermarket, Here’s the Reason - Stocks Telegraph

      By Hassan Masood

      Published on

      October 21, 2021

      4:27 AM UTC

      Last Updated on

      June 19, 2023

      11:58 AM UTC

      ADMA Biologics, Inc. (ADMA) Stock Declining in Aftermarket, Here’s the Reason - Stocks Telegraph

      ADMA Biologics, Inc. (ADMA), a biopharmaceutical company, has declined 7.21% in the aftermarket trading session and is trading at $1.03 at the time of this writing. The apparent reason for the decline is the announcement of the proposed public offering of common stock. On Wednesday, ADMA stock closed the day at $1.11.

      ADMA announced the public offering of stock

      ADMA announced on Wednesday that it intends to offer the shares of its common stock for sale in an underwritten public offering. The company said that it intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold about the connection. The offering was subject to market and related conditions.

      There were no assurances as to whether and when the offering would be completed or to the actual size and term of the offering. The company intended to use the net proceeds from the offering to advance the commercial sales of US FDA approved products, for expansion of its plasma collection facility network, to scale up the manufacturing capacity of its Boca Raton facility, to explore business development opportunities, and for general corporate and capital expenditures. Raymond James & Associates, Inc. and Cantor Fitzgerald & Co. were serving as the joint book-running managers for the offering.

      Q2 2021 financial highlights

      On 11th August, ADMA reported the financial results for the second quarter of the fiscal year 2021 which ended on 30th June 2021. The company had cash and cash equivalents of $42.40 million on 30th June. The total assets in possession of the company at the time were $232.81 million while the total liabilities were $121.22 million.

      ADMA Biologics, Inc. (ADMA) generated total revenue of $17.83 million during the quarter against $7.78 million for the same quarter of 2020. The total operating expenses for the period were $33.41 million against $24.91 million for the same period of 2020.

      The company suffered a loss of $15.58 million from the operations during the period against $17.18 million for the same period of 2020. The net loss for the three months was $18.90 million against the net loss of $20.17 million for the same period of 2020. The net loss per basic and diluted share for the period was $0.15 during the quarter against $0.23 for the same period of 2020.

      What’s the future for ADMA?

      During the last three months, ADMA has declined more than 25% Estimates suggest that due to business expansion strategies and reliance upon innovation, ADMA stock earnings per share could increase more than 50% during the next fiscal year. So, potential investors should keep a close eye on ADMA stock.

      More From Stocks telegraph